Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited demonstrates strong business quality, financial strength, and a favorable valuation score. While profitability and growth metrics are solid, the company's intrinsic value analysis suggests a current overvaluation based on the provided DCF assumptions. Cash flow generation has shown variability, with a recent dip in Free Cash Flow.
Business Performance (CAGR)
Valuation Snapshot
Financial Health
Profitability Metrics
Cash Flow Intelligence
Intrinsic Value
PremiumEstimated Intrinsic Value & DCF Fair Value are available with Premium plans.
AI Business Verdict
Dr. Reddy's Laboratories is a financially robust company with a track record of strong revenue and profit growth. While its operational performance and financial health are commendable, the current market valuation appears elevated when compared to its calculated intrinsic value. Future performance will depend on its ability to convert profits into consistent Free Cash Flow and optimize capital deployment for sustainable shareholder value creation.
- Robust financial strength with a low debt-to-equity ratio and high interest coverage.
- Consistent double-digit revenue, net profit, and EPS growth rates.
- High-quality earnings demonstrated by an OCF to PAT ratio exceeding 100%.
- Strong market position as a Large Cap pharmaceutical company.
Balance Sheet
Dr. Reddy's Laboratories Limited maintains a balanced sheet with adequate liquidity and manageable leverage.
Capacity to fund growth, withstand downturns and return capital.
- Dr.
- Reddy's Laboratories Limited maintains a balanced sheet with adequate liquidity and manageable leverage.
- Net cash position — debt fully covered by cash & investments
- Large cash & investment reserves
- Very low leverage with net cash balance
- Strong shareholder equity growth
- High interest coverage
- Long working capital cycle
- Large 'other assets' bucket — investigate composition